Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
The Road to the April 2020 Withdrawal
The FDA's April 2020 market withdrawal request was the culmination of approximately 10 months of investigation triggered by Valisure's June 2019 Citizen Petition. Between June 2019 and April 2020, the following key events occurred: The FDA confirmed Valisure's core finding that NDMA was present in ranitidine products. Multiple manufacturers voluntarily recalled specific lots of prescription ranitidine in late 2019 and early 2020. Retailers including Walgreens, CVS, Walmart, and Rite Aid voluntarily pulled ranitidine products from their shelves in late 2019 and early 2020. The FDA issued an updated market alert in April 2020 based on its conclusion that NDMA levels in ranitidine increase over time under normal storage conditions, which made any piecemeal lot-specific recall approach inadequate. The FDA also noted that new testing methodology (simulated in vivo testing) showed dramatically higher NDMA levels than the original static testing, reinforcing the need for a comprehensive market action.
What the April 2020 FDA Action Means Legally
The FDA's April 2020 market withdrawal request is significant in Zantac litigation for multiple reasons. First, it establishes that the FDA — the federal regulatory body responsible for pharmaceutical safety — concluded that ranitidine products posed an unacceptable risk of NDMA exposure and ordered them off the market. This is powerful evidence of the defective and unreasonably dangerous nature of ranitidine products. Second, it establishes April 2020 as the latest date of constructive public notice of the Zantac-NDMA risk — meaning statutes of limitations in many states began running no later than April 2020. Third, the FDA's finding that ranitidine instability is inherent to the molecule — not the result of particular storage or handling conditions — undercuts any defense argument that manufacturers exercised reasonable care in formulation and that NDMA levels in typical consumer doses were safe.
The FDA Will Not Approve New Ranitidine Products
As part of its April 2020 action, the FDA announced that it would not accept new drug applications (NDAs) or abbreviated new drug applications (ANDAs) for ranitidine products until manufacturers could demonstrate a feasible approach to eliminating NDMA formation — something the FDA deemed unlikely given the inherent instability of the ranitidine molecule. This permanent bar on new ranitidine approvals is the FDA's implicit acknowledgment that the problem cannot be fixed by manufacturing process changes. Consumers who relied on ranitidine for GERD and heartburn management have been directed to famotidine (Pepcid), cimetidine (Tagamet), or proton pump inhibitors (Prilosec, Nexium, Prevacid), all of which are NDMA-free and available OTC.
Timeline of FDA Actions on Ranitidine
June 2019: Valisure files FDA Citizen Petition reporting NDMA in ranitidine at 3,000x+ the daily limit. September 2019: FDA alerts healthcare professionals and patients to NDMA in ranitidine; requests manufacturer testing. October-November 2019: Multiple manufacturers and retailers initiate voluntary recalls and shelf removals. January-March 2020: FDA testing of ranitidine samples confirms NDMA levels above acceptable limits and confirms instability under storage conditions. April 1, 2020: FDA requests immediate market withdrawal of all prescription and OTC ranitidine products from all manufacturers nationwide. April 2020 onward: FDA states it will not accept new drug applications for ranitidine products.
Key data
Data & Statistics
April 1, 2020: FDA requested all ranitidine manufacturers withdraw products from the U.S. market — prescription and OTC
FDA press release, April 1, 2020
FDA will not accept new drug applications for ranitidine products due to inherent NDMA instability
FDA April 2020 market withdrawal guidance
FAQ
Frequently Asked Questions
Dive deeper
Related Guides
- Zantac NDMA Contamination ExplainedNDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.
- The Valisure Study — How the NDMA Problem Was DiscoveredValisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.
- Zantac Settlement Expectations — State Court Litigation 2026Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
- Zantac Statute of Limitations — State-by-State 2026 AnalysisThe statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
- Cancers Covered by Zantac LitigationSix cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.
- Zantac and Bladder CancerBladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
- Zantac Federal MDL Dismissal — What HappenedThe federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.
- Zantac State Court Litigation — Delaware and California 2026Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.
- Zantac Eligibility RequirementsTo qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.
- Zantac Brand vs. Generic — All Manufacturers Are LiableThe NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.
- Proving Zantac Use — How to Obtain Pharmacy RecordsPharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
The full investigation